On this page:Overview Publications Researchers Institutions Open access

ScholarIQanswers from OpenAlex

UCB Pharma (United States)

InstitutionResearch output, impact & collaborations

UCB Pharma (United States) is a institution indexed in ScholarIQ from OpenAlex.

What is known about UCB Pharma (United States)?

ScholarIQrecord summary

UCB Pharma (United States) is a research organisation in Atlanta, US. OpenAlex records 927 works and 49,708 citations for it. 181 researchers list it as their most recent affiliation.

How many works does UCB Pharma (United States) have?

ScholarIQindexed works

UCB Pharma (United States) has 927 works in the ScholarIQ index. The count is the OpenAlex total, not the number of papers listed on this page.

See the works listed for UCB Pharma (United States) →

How many citations does UCB Pharma (United States) have?

ScholarIQcitation count

UCB Pharma (United States) has 49,708 citations in the OpenAlex counts ScholarIQ stores.

See the listed works for UCB Pharma (United States) →

How many researchers are at UCB Pharma (United States)?

ScholarIQresearcher count

UCB Pharma (United States) has 181 researchers in the ScholarIQ index.

See the researchers listed on this page →

What is the average h-index at UCB Pharma (United States)?

ScholarIQavg h-index

UCB Pharma (United States) has an average h-index of 15 in OpenAlex.

Open the OpenAlex record →

What is the ROR of UCB Pharma (United States)?

ScholarIQror

The ROR for UCB Pharma (United States) is on the source record.

Open the ROR →

What is the OpenAlex record for UCB Pharma (United States)?

ScholarIQopenalex

The OpenAlex for UCB Pharma (United States) is on the source record.

Open the OpenAlex →

Who are the most-cited researchers behind UCB Pharma (United States)?

ScholarIQtop researchers by citations

Tom Richardson · Error Correcting Code Techniques

68 works16,240 citations

Prajakta P. Masurkar · Pharmaceutical Practices and Patient Outcomes

32 works119 citations

What are the most-cited papers on UCB Pharma (United States)?

ScholarIQmost cited works

Cost Effectiveness of CDK4/6 Inhibitors in the First-Line Treatment of HR+/HER2− Metastatic Breast Cancer in Postmenopausal Women in the USA

Prajakta P. Masurkar, Haluk Damgacioglu, Ashish A. Deshmukh, Meghana V. Trivedi

PharmacoEconomics. 202326 Citations

Risk of Serious Adverse Events Associated With Individual Cholinesterase Inhibitors Use in Older Adults With Dementia: A Population-Based Cohort Study

Prajakta P. Masurkar, Satabdi Chatterjee, Jeffrey T. Sherer, Hua Chen, Michael L. Johnson, Rajender R. Aparasu

Drugs & Aging. 202218 Citations

Cost-effectiveness of CDK4/6 inhibitors in HR+/HER2− metastatic breast cancer: a systematic review and meta-analysis

Prajakta P. Masurkar, Prachi Prajapati, Joanne Canedo, Swarnali Goswami, Sally Earl, Kaustuv Bhattacharya

Current Medical Research and Opinion. 202411 Citations

Antimuscarinic Cascade Across Individual Cholinesterase Inhibitors in Older Adults with Dementia

Prajakta P. Masurkar, Satabdi Chatterjee, Jeffrey T. Sherer, Rajender R. Aparasu

Drugs & Aging. 20218 Citations

A naturalistic observation study of medication counseling practices at retail chain pharmacies

S. Yande, Prajakta P. Masurkar, Suma Gopinathan, Sujit S. Sansgiry

Pharmacy Practice. 20207 CitationsOPEN ACCESS

How much of the research on UCB Pharma (United States) is open access?

ScholarIQopen access share

40%OPEN ACCESS

Gold

20%

Green

10%

Hybrid

10%

Bronze

Closed

60%